W Todd Cade1, Dominic N Reeds2, E Turner Overton3, Pilar Herrero4, Alan D Waggoner5, Erin Laciny6, Coco Bopp6, Sherry Lassa-Claxton6, Robert J Gropler4, Linda R Peterson5, Kevin E Yarasheski6. 1. Program in Physical Therapy, Washington University School of Medicine, St. Louis, Missouri. 2. Division of Geriatrics and Nutritional Science, Washington University School of Medicine, St. Louis, Missouri. 3. Division of Infectious Disease, Washington University School of Medicine, St. Louis, Missouri. 4. Department of Radiology, Washington University School of Medicine, St. Louis, Missouri. 5. Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri. 6. Division of Endocrinology, Metabolism, & Lipid Research, Washington University School of Medicine, St. Louis, Missouri.
Abstract
BACKGROUND:Individuals with HIV infection and peripheral metabolic complications have impaired basal myocardial insulin sensitivity that is related to left ventricular (LV) diastolic dysfunction. It is unknown whether interventions shown to be effective in improving peripheral insulin sensitivity can improve basal myocardial insulin sensitivity and diastolic function in people with HIV and peripheral metabolic complications. OBJECTIVE: In a pilot study, we evaluated whether the peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist pioglitazone or combined endurance and resistance exercise training improves basal myocardial insulin sensitivity and diastolic function in HIV+ adults with peripheral metabolic complications. DESIGN:Twenty-four HIV+ adults with metabolic complications including peripheral insulin resistance were randomly assigned to 4 months of pioglitazone (PIO; 30 mg/d) or supervised, progressive endurance and resistance exercise training (EXS; 90-120 min/d, 3 d/wk). Basal myocardial substrate metabolism was quantified by radioisotope tracer methodology and positron emission tomography (PET) imaging, and LV function was measured by echocardiography. RESULTS:Twenty participants completed the study. Neither PIO nor EXS resulted in a detectable improvement in basal myocardial insulin sensitivity or diastolic function. Post hoc analyses revealed sample sizes of more than 100 participants are needed to detect significant effects of these interventions on basal myocardial insulin sensitivity and function. CONCLUSIONS:PIO or EXS alone did not significantly increase basal myocardial insulin sensitivity or LV diastolic function in HIV+ individuals with peripheral metabolic complications.
RCT Entities:
BACKGROUND: Individuals with HIV infection and peripheral metabolic complications have impaired basal myocardial insulin sensitivity that is related to left ventricular (LV) diastolic dysfunction. It is unknown whether interventions shown to be effective in improving peripheral insulin sensitivity can improve basal myocardial insulin sensitivity and diastolic function in people with HIV and peripheral metabolic complications. OBJECTIVE: In a pilot study, we evaluated whether the peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist pioglitazone or combined endurance and resistance exercise training improves basal myocardial insulin sensitivity and diastolic function in HIV+ adults with peripheral metabolic complications. DESIGN: Twenty-four HIV+ adults with metabolic complications including peripheral insulin resistance were randomly assigned to 4 months of pioglitazone (PIO; 30 mg/d) or supervised, progressive endurance and resistance exercise training (EXS; 90-120 min/d, 3 d/wk). Basal myocardial substrate metabolism was quantified by radioisotope tracer methodology and positron emission tomography (PET) imaging, and LV function was measured by echocardiography. RESULTS: Twenty participants completed the study. Neither PIO nor EXS resulted in a detectable improvement in basal myocardial insulin sensitivity or diastolic function. Post hoc analyses revealed sample sizes of more than 100 participants are needed to detect significant effects of these interventions on basal myocardial insulin sensitivity and function. CONCLUSIONS:PIO or EXS alone did not significantly increase basal myocardial insulin sensitivity or LV diastolic function in HIV+ individuals with peripheral metabolic complications.
Entities:
Keywords:
HIV; exercise; insulin resistance; left ventricular dysfunction; metabolic syndrome
Authors: K E Yarasheski; P Tebas; B Stanerson; S Claxton; D Marin; K Bae; M Kennedy; W Tantisiriwat; W G Powderly Journal: J Appl Physiol (1985) Date: 2001-01
Authors: C Hadigan; J B Meigs; C Corcoran; P Rietschel; S Piecuch; N Basgoz; B Davis; P Sax; T Stanley; P W Wilson; R B D'Agostino; S Grinspoon Journal: Clin Infect Dis Date: 2000-12-15 Impact factor: 9.079
Authors: Kevin E Yarasheski; W Todd Cade; E Turner Overton; Kristin E Mondy; Sara Hubert; Erin Laciny; Coco Bopp; Sherry Lassa-Claxton; Dominic N Reeds Journal: Am J Physiol Endocrinol Metab Date: 2010-10-19 Impact factor: 4.310
Authors: W Todd Cade; Dominic N Reeds; E Turner Overton; Pilar Herrero; Alan D Waggoner; Victor G Davila-Roman; Sherry Lassa-Claxton; Robert J Gropler; Pablo F Soto; Melissa J Krauss; Kevin E Yarasheski; Linda R Peterson Journal: Cardiovasc Diabetol Date: 2011-12-08 Impact factor: 9.951
Authors: Suman Srinivasa; Teressa S Thomas; Meghan N Feldpausch; Gail K Adler; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 5.958
Authors: Amanda L Willig; Allison R Webel; Andrew O Westfall; Emily B Levitan; Heidi M Crane; Thomas W Buford; Greer A Burkholder; James H Willig; Aaron J Blashill; Richard D Moore; W Christopher Mathews; Anne Zinski; Josh Muhammad; Elvin H Geng; Sonia Napravnik; Joseph J Eron; Benigno Rodriguez; Marcas M Bamman; E Turner Overton Journal: Prog Cardiovasc Dis Date: 2020-02-12 Impact factor: 8.194